Furthermore, a study evaluating AR ChIP-sequencing of patient tissue (normal n  = 4, localised n  = 4, metastatic n  = 3, and CRPC n  = 3) identified that at every stage of prostate cancer, there is a distinct binding pattern for AR (Stelloo et al. 2015). This evidence concerns the gene AR and prostate carcinoma.